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Background: Patients with hypertrophic cardiomyopathy (HCM) have coronary vascular dysfunction but the extent to which vascular dysfunction 
is systemic remains unclear. Pulse wave amplitude (PWA) and augmentation index (AI) are measures of systemic vascular function associated with 
cardiovascular risk. Altered timing/magnitude of pressure from wave reflections, manifesting as an elevated AI, increases late systolic load and as 
such is associated with systolic and diastolic dysfunction, left ventricular (LV) hypertrophy, reduced coronary perfusion, and reduced subendocardial 
perfusion; all clinically relevant facets of HCM pathology. The purpose of this study was to examine AI and PWA in patients with HCM and age-
matched controls without HCM.
Methods: PWA was measured by peripheral arterial tonometry (PAT) and used to calculate AI (the ratio of the difference between the early and 
late systolic peaks of the waveform relative to the early peak expressed as a percentage) in 44 patients with HCM without left ventricular outflow 
tract (LVOT) obstruction (mean age 44±2 years) and 77 control patients without HCM (mean age 47±2 years). Cardiac structure was assessed 
using conventional 2-D echocardiography. Patients with LVOT obstruction were excluded owing to the “bisferiens” pulse waveform often produced by 
aberrant pressure and flow patterns secondary to LVOT obstruction in this cohort.
Results: Compared to controls, patients with HCM had significantly higher AI (HCM, 5.6 ± 3.5 %; Controls, -8.7 ± 1.7 %; p<0.05) and PWA (HCM, 
647 ± 50; Controls, 370 ± 36 units; p<0.05). Group differences remained after adjusting for heart rate. In patients with HCM, AI was correlated with 
LA size (r = 0.27, p<0.05) while PWA was correlated with left ventricular end diastolic dimension (r = 0.34, p<0.05) and left atrial size (r = 0.33, 
p<0.05).
Conclusions: Patients with HCM without LVOT obstruction have systemic vascular dysfunction as demonstrated by elevated peripheral AI and PWA. 
Peripheral vascular dysfunction is associated with LA size, a previously established predictor of mortality and correlate of LV dysfunction in HCM.
